Providing an educational resource for individuals to learn more about hereditary ATTR (hATTR) amyloidosis
hATTR amyloidosis is an autosomal dominant disorder caused by mutations in the transthyretin (TTR) gene. In the disease continuum of hATTR amyloidosis, some individuals present primarily with polyneuropathy symptoms, historically known as familial amyloidotic polyneuropathy (FAP), and other individuals present primarily with cardiomyopathy symptoms, historically known as familial amyloidotic cardiomyopathy (FAC).
The time for education is now
The Bridge™ program is about providing education, spreading awareness, and facilitating conversation about hATTR amyloidosis among affected individuals and their families.
The Bridge™ provides individuals with an array of educational resources designed to help them and their family. The Bridge is also a valuable resource for undiagnosed individuals who may be experiencing symptoms or know of a family member who is diagnosed and wants to learn more about hATTR amyloidosis.
Alnylam is sponsoring no-charge third-party genetic testing and counseling for individuals who may carry a gene mutation known to be associated with hereditary ATTR (hATTR) amyloidosis. The Alnylam Act® program was developed to reduce barriers to genetic testing and counseling to help people make more informed decisions about their health. While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for healthcare professionals who use this program. Genetic testing is available in the U.S. and Canada. Genetic counseling is only available in the U.S. Healthcare professionals who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.
Genetic testing and counseling may help to:
- Identify risk of disease for patients and their family members
- Shorten the time to diagnosis and prevent misdiagnoses
- Determine if patients are eligible to participate in clinical trials
- Provide information about support resources such as patient advocacy organizations
Resources for Healthcare Professionals
Neuropathic Red-flag Symptoms Flashcard
A guide to the key symptoms of hATTR amyloidosis for neurologists
Resources for Patients
Family Discussion Guide
Tips for starting the conversation with your family and a list of resources for further education
A Closer Look at hATTR Amyloidosis
An overview of how the condition occurs, its hereditary nature, and the symptoms that individuals may experience
Family Health Tree
A tool to help patients map their family’s history of hATTR amyloidosis, including symptom tracking, diagnosis time, and more
Healthcare Professional Discussion Guide
Information and tips for talking to your healthcare professional about hATTR amyloidosis
Healthcare Professional Fact Sheet
An informational flashcard that individuals can provide to their healthcare professional to help educate about hATTR amyloidosis
Family History Book
A powerful story about one family's battle with hATTR amyloidosis over the course of four generations and their determination to move foward